Home hover Guidelines hover Expert hover Compare hover Faq hover Submit hover About hover Resources hover Syntheses hover Myngc hover Guidelinematrix hover
Home
Browse Guidelines
Expert Commentaries
Guideline Syntheses
Guideline Matrix
Guideline Resources
Compare Guidelines
Frequently Asked Questions
Submit Guidelines
About
myNGC
< Back

'epidermal growth factor receptor'
Run an advanced search on this term

Search within:  

Sort results by:      



Filter results by:

1-20 of 42   Next >
 
1.  
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer. 2014 Apr. NGC:010348
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
2.  
Epidermal growth factor receptor (EGFR) targeted therapy in stage III and IV head and neck cancer. 2009 May 15 (revised 2011 Sep 30). NGC:009855
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
3.  
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. 2007 Jan 1 (revised 2013 Nov 1). NGC:010054
American Society of Clinical Oncology - Medical Specialty Society; College of American Pathologists - Medical Specialty Society. View all guidelines by the developer(s)
7.  
Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy. 2013 Aug. NGC:010011
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
8.  
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. 2010 Jul. NGC:008066
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
9.  
EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. 2013 Aug. NGC:010540
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
10.  
Prevention and treatment of rash in patients treated with EGFR inhibitor therapies. 2012 May. NGC:010391
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
12.  
Staging investigations for asymptomatic and newly diagnosed breast cancer. 2012 Jul. NGC:009378
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
13.  
Non-small cell lung cancer stage IV. 2011 Jun (revised 2013 Nov). NGC:010261
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
14.  
The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. 2010 Jan. NGC:008368
American Association of Neurological Surgeons - Medical Specialty Society; Congress of Neurological Surgeons - Professional Association. View all guidelines by the developer(s)
15.  
Optimal use of taxanes in metastatic breast cancer (MBC). 2013 Sep. NGC:010373
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
16.  
First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer. 2009 May 22 (revised 2010 Feb 3). NGC:007692
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
19.  
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 2013 Jun. NGC:009787
Association for Molecular Pathology - Medical Specialty Society; College of American Pathologists - Medical Specialty Society; International Association for the Study of Lung Cancer - Disease Specific Society. View all guidelines by the developer(s)
20.  
Treatment of primary breast cancer. A national clinical guideline. 1998 Oct (revised 2013 Sep). NGC:010022
Scottish Intercollegiate Guidelines Network - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
1-20 of 42   Next >